<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="6568">
  <stage>Registered</stage>
  <submitdate>30/04/2016</submitdate>
  <approvaldate>30/04/2016</approvaldate>
  <nctid>NCT02763319</nctid>
  <trial_identification>
    <studytitle>A Trial to Evaluate the Efficacy and Safety of MOR208 With Bendamustine (BEN) Versus Rituximab (RTX) With BEN in Adult Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma (DLBCL)</studytitle>
    <scientifictitle>A Phase 2/3, Randomised, Multicentre Study of MOR208 With Bendamustine Versus Rituximab With Bendamustine in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (R-R DLBCL) Who Are Not Eligible for High-Dose Chemotherapy (HDC) and Autologous Stem-Cell Transplantation (ASCT)</scientifictitle>
    <utrn />
    <trialacronym>B-MIND</trialacronym>
    <secondaryid>2014-004689-11</secondaryid>
    <secondaryid>MOR208C204</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Diffuse Large B-cell Lymphoma</healthcondition>
    <conditioncode>
      <conditioncode1>Cancer</conditioncode1>
      <conditioncode2>Lymphoma (non Hodgkin's lymphoma) - High grade lymphoma</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Cancer</conditioncode1>
      <conditioncode2>Lymphoma (non Hodgkin's lymphoma) - Low grade lymphoma</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Treatment: drugs - Rituximab (RTX)
Treatment: drugs - MOR208
Treatment: drugs - Bendamustine (BEN)

Experimental: MOR208 and bendamustine - MOR208 and bendamustine

Active Comparator: Rituximab and bendamustine - Rituximab and bendamustine


Treatment: drugs: Rituximab (RTX)
Rituximab: Dose: 375 mg/m2 IV

Treatment: drugs: MOR208
MOR208: MOR208 dose: 12 mg/kg intravenously (IV)

Treatment: drugs: Bendamustine (BEN)


</interventions>
    <comparator />
    <control />
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Progression-free survival (PFS) - To determine the efficacy of a combination of MOR208 with BEN versus a combination of RTX with BEN in terms of progression-free survival (PFS) in adult patients with R-R DLBCL.</outcome>
      <timepoint>From date of randomization until recurrence/disease progression, unacceptable toxicity, death or discontinuation for any other reason, whichever comes first assessed up to 4 yrs</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Objective response rate (ORR) - To determine efficacy</outcome>
      <timepoint>From date of randomization assessed up to 4 yrs</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Duration of response (DoR) - To determine efficacy</outcome>
      <timepoint>From date of randomization assessed up to 4 yrs</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>overall survival (OS) - To determine efficacy</outcome>
      <timepoint>From date of randomization assessed up to 4 yrs</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>disease control rate (DCR) - To determine efficacy</outcome>
      <timepoint>From date of randomization assessed up to 4 yrs</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>time to progression (TTP) - To determine efficacy</outcome>
      <timepoint>From date of randomization assessed up to 4 yrs</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>time to next treatment (TTNT) - To determine efficacy</outcome>
      <timepoint>From date of randomization assessed up to 4 yrs</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Number of patients with adverse events - Number of participants with treatment- and non-treatment related adverse events as assessed by CTCAE</outcome>
      <timepoint>assessed up to 4 yrs</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>quality of life (QoL) - EORTC QLQ-C30 questionnaire will be used</outcome>
      <timepoint>assessed up to 4 yrs</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Number of patients developing MOR208 antibodies</outcome>
      <timepoint>assessed up to 2 yrs</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Maximum Plasma Concentration of MOR208 (Cmax)</outcome>
      <timepoint>assessed up to 2 yrs</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Apparent trough concentration (Cpd) of MOR00208</outcome>
      <timepoint>assessed up to 2 yrs</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>INCLUSION CRITERIA:

          1. Age =18 years

          2. Histologically confirmed diagnosis, according to the World Health Organization (WHO,
             2008) classification, of: DLBCL NOS, THRLBCL, EBV-positive DLBCL, composite lymphoma
             with a DLBCL component with a DLBCL relapse subsequent to DLBCL treatment, disease
             transformed from an earlier diagnosis of low grade lymphoma (i.e. an indolent
             pathology such as follicular lymphoma, marginal zone lymphoma) into DLBCL with a DLBCL
             relapse subsequent to DLBCL treatment.

          3. Fresh tumour tissue for central pathology review must be provided as an adjunct to
             participation in this study. Should it not be possible to obtain a fresh tumour tissue
             sample, archival paraffin embedded tumour tissue acquired =3 years prior to screening
             for this protocol must be available for this purpose.

          4. Patients must have:

               1. relapsed or refractory DLBCL

               2. at least one bidimensionally measurable disease site. The lesion must have a
                  greatest transverse diameter of =1.5 cm and greatest perpendicular diameter of
                  =1.0 cm at baseline. The lesion must be positive on PET scan

               3. received at least one, but no more than three previous systemic therapy lines for
                  the treatment of DLBCL. At least one previous therapy line must have included a
                  CD20-targeted.

               4. ECOG 0 to 2

          5. Patients after failure of ASCT or patients considered in the opinion of the
             investigator currently not eligible for HDC with subsequent ASCT.

          6. Patients must meet the following laboratory criteria at Screening:

               1. ANC =1.5 × 109/L (unless secondary to bone marrow involvement by DLBCL)

               2. PLTs =90 × 109/L (unless secondary to bone marrow involvement by DLBCL) and
                  absence of active bleeding

               3. total serum bilirubin =2.5 × ULN unless secondary to Gilbert's syndrome (or
                  pattern consistent with Gilbert's) or documented liver involvement by lymphoma.
                  Patients with Gilbert's syndrome or documented liver involvement by lymphoma may
                  be included if their total bilirubin is =5 x ULN

               4. ALT, AST and AP =3 × ULN or &lt;5 × ULN in cases of documented liver involvement by
                  lymphoma

               5. serum creatinine =2.0 x ULN or creatinine clearance must be =40 mL/min calculated
                  using a standard Cockcroft-Gault formula (Cockroft &amp; Gault, 1976)

          7. For a female of childbearing potential (FCBP), a negative pregnancy test must be
             confirmed before enrolment. An FCBP must commit to take highly effective contraceptive
             precautions without interruption during the study and for 3, 6 or 12 months after the
             last dose of MOR00208, BEN or RTX respectively, whichever is later. An FCBP must
             refrain from breastfeeding and donating blood or oocytes during the course of the
             study and for 3, 6 or 12 months after the last dose of MOR00208, BEN or RTX
             respectively, whichever is later. Restrictions concerning blood donations apply as
             well to females who are not of childbearing potential.

          8. Males must use an effective barrier method of contraception without interruption
             during the study and for 3, 6 or 12 months after the last dose of MOR00208, BEN or RTX
             respectively, whichever is later, if the patient is sexually active with an FCBP.
             Males must refrain from donating blood or sperm during study participation and for 3,
             6 or 12 months after the last dose of MOR00208, BEN or RTX respectively, whichever is
             later.

          9. In the opinion of the investigator, the patients must:

               1. be able to comply with all study-related procedures, medication use, and
                  evaluations

               2. be able to understand and give informed consent

               3. not be considered to be potentially unreliable and/or not cooperative.

        EXCLUSION CRITERIA:

          1. Patients who have: any other histological type of lymphoma including, e.g., primary
             mediastinal (thymic) large B-cell lymphoma (PMBL) or Burkitt's lymphoma, primary
             refractory DLBCL, patients with known "double/triple hit" DLBCL genetics, CNS lymphoma
             involvement in present or past medical history

          2. Patients who had a major surgery less than 30 days prior to Day 1 dosing

          3. Patients who have, within 14 days prior to Day 1 dosing:

               1. not discontinued CD20-targeted therapy, chemotherapy, radiotherapy,
                  investigational anticancer therapy or other lymphoma-specific therapy

               2. received live vaccines

               3. required parenteral antimicrobial therapy for active, intercurrent systemic
                  infections

          4. Patients who:

               1. in the opinion of the investigator, have not recovered sufficiently from the
                  adverse toxic effects of prior therapies, major surgeries or significant
                  traumatic injuries

               2. were previously treated with CD19-targeted therapy or BEN

               3. have a history of previous severe allergic reactions to compounds of similar
                  biological or chemical composition to MOR00208, RTX, murine proteins or BEN, or
                  the excipients contained in the study drug formulations

               4. have undergone ASCT within a period of =3 months prior to signing the informed
                  consent form. Patients who have a more distant history of ASCT must exhibit full
                  haematological recovery before enrolment into the study.

               5. have undergone previous allogeneic stem cell transplantation

               6. concurrently use other anticancer or experimental treatments

          5. Prior history of malignancies other than DLBCL, unless the patient has been free of
             the disease for =3 years prior to Screening. Exceptions to the =3-year time limit
             include history of the following:

               1. basal cell carcinoma of the skin

               2. squamous cell carcinoma of the skin

               3. carcinoma in situ of the cervix, breast and bladder

             f) incidental histological finding of prostate cancer (Tumour/Node/Metastasis [TNM]
             stage of T1a or T1b)

          6. Patients with:

               1. positive hepatitis B and/or C serology

               2. known seropositivity for or history of active viral infection with HIV

               3. evidence of active, severe uncontrolled systemic infections or sepsis

               4. a history or evidence of severely immunocompromised state

               5. a history or evidence of severe hepatic impairment (total serum bilirubin &gt; 3
                  mg/dL), jaundice unless secondary to Gilbert's syndrome or documented liver
                  involvement by lymphoma

               6. a history or evidence of clinically significant cardiovascular, cerebrovascular,
                  CNS and/or other disease that, in the investigator's opinion, would preclude
                  participation in the study or compromise the patient's ability to give informed
                  consent</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage />
    <inclusivemaxagetype>No limit</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria />
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3>The people assessing the outcomes</masking3>
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 2/Phase 3</phase>
    <anticipatedstartdate />
    <actualstartdate>1/06/2016</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize>330</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Recruiting</recruitmentstatus>
    <anticipatedlastvisitdate>1/03/2022</anticipatedlastvisitdate>
    <actuallastvisitdate />
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate />
    <hospital>MorphoSys Research Site - Adelaide</hospital>
    <hospital>MorphoSys Research Site - Albury</hospital>
    <hospital>MorphoSys Research Site - Bedford Park</hospital>
    <hospital>MorphoSys Research Site - Geelong</hospital>
    <hospital>MorphoSys Research Site - Gosford</hospital>
    <hospital>MorphoSys Research Site - Melbourne</hospital>
    <hospital>MorphoSys Research Site - South Brisbane</hospital>
    <postcode>5000 - Adelaide</postcode>
    <postcode>2640 - Albury</postcode>
    <postcode>5042 - Bedford Park</postcode>
    <postcode>3220 - Geelong</postcode>
    <postcode>2250 - Gosford</postcode>
    <postcode>3021 - Melbourne</postcode>
    <postcode>3128 - Melbourne</postcode>
    <postcode>4101 - South Brisbane</postcode>
    <countryoutsideaustralia>
      <country>Austria</country>
      <state>Innsbruck</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Austria</country>
      <state>Salzburg</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Croatia</country>
      <state>Zadar</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Croatia</country>
      <state>Zagreb</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Czechia</country>
      <state>Hradec Kralove</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Czechia</country>
      <state>Prague</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Finland</country>
      <state>Oulu</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Finland</country>
      <state>Tampere</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Chalon sur Saône</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Grenoble</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Le Mans</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Perigueux</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Aachen</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Berlin</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Duesseldorf</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Giessen</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Leipzig</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Mainz</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Munich</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Mutlangen</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Stuttgart</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Traunstein</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Hungary</country>
      <state>Gyor</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Hungary</country>
      <state>Szeged</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Israel</country>
      <state>Haifa</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Israel</country>
      <state>Jerusalem</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Israel</country>
      <state>Kfar Saba</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Israel</country>
      <state>Nahariya</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Israel</country>
      <state>Peta? Tiqwa</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Israel</country>
      <state>Re?ovot</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Israel</country>
      <state>Tel Aviv</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Italy</country>
      <state>Alessandria</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Italy</country>
      <state>Campobasso</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Italy</country>
      <state>Cona</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Italy</country>
      <state>Genova</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Italy</country>
      <state>Lecce</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Italy</country>
      <state>Meldola</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Italy</country>
      <state>Monza</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Italy</country>
      <state>Napoli</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Italy</country>
      <state>Parma</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Italy</country>
      <state>Pavia</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Italy</country>
      <state>Pisa</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Italy</country>
      <state>Ravenna</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Italy</country>
      <state>Reggio Emilia</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Italy</country>
      <state>Rimini</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Italy</country>
      <state>Rome</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Korea, Republic of</country>
      <state>Busan</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Korea, Republic of</country>
      <state>Goyang-si</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Korea, Republic of</country>
      <state>Incheon</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Korea, Republic of</country>
      <state>Jeonju-si</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Korea, Republic of</country>
      <state>Seongnam</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Korea, Republic of</country>
      <state>Seoul</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Korea, Republic of</country>
      <state>Ulsan</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>New Zealand</country>
      <state>Addington</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>New Zealand</country>
      <state>Auckland</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Poland</country>
      <state>Bydgoszcz</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Poland</country>
      <state>Gdansk</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Poland</country>
      <state>Gdynia</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Poland</country>
      <state>Krakow</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Poland</country>
      <state>Kraków</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Poland</country>
      <state>Lodz</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Portugal</country>
      <state>Braga</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Portugal</country>
      <state>Coimbra</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Portugal</country>
      <state>Matosinhos</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Portugal</country>
      <state>Porto</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Romania</country>
      <state>Bucharest</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Singapore</country>
      <state>Singapore</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Spain</country>
      <state>Cadiz</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Spain</country>
      <state>Girona</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Spain</country>
      <state>Madrid</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Spain</country>
      <state>Palma de Mallorca</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Spain</country>
      <state>Pamplona</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Spain</country>
      <state>Sabadell</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Spain</country>
      <state>Salamanca</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Spain</country>
      <state>Valencia</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Turkey</country>
      <state>Ankara</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Turkey</country>
      <state>Bornova</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Turkey</country>
      <state>Izmir</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Turkey</country>
      <state>Manisa</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United Kingdom</country>
      <state>Leeds</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United Kingdom</country>
      <state>Southend on Sea</state>
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>MorphoSys AG</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
    <othercollaborator>
      <othercollaboratortype>Commercial sector/Industry</othercollaboratortype>
      <othercollaboratorname>ICON Clinical Research</othercollaboratorname>
      <othercollaboratoraddress />
      <othercollaboratorcountry />
    </othercollaborator>
  </sponsorship>
  <ethicsAndSummary>
    <summary>The purpose of the study is to compare the safety and efficacy of MOR208 with BEN versus RTX
      with BEN in adult patients with relapsed of refractory DLBCL.</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT02763319</trialwebsite>
    <publication />
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Grzegorz Nowakowski, MD</name>
      <address>Mayo Clinic</address>
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name>Roman P Korolkiewicz, MD</name>
      <address />
      <phone>+49 89 89927 0</phone>
      <fax />
      <email>roman.korolkiewicz@morphosys.com</email>
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>